Abstract:Glycosylation is a tightly regulated post-translational modification where structured sugar groups are added to protein amino acid backbones, most commonly on asparagine for N-glycosylation. The glycosylation-regulating metabolic enzyme uridine diphosphate-glucose pyrophosphorylase 2 (UGP2) is required in oncogene-transformed cancer cells, but not in normal cells. UGP2 heavily regulates glycosylation of epidermal growth factor receptor (EGFR) at asparagine 361 (N361), a key site near the ligand binding domain. EGFR is a transmembrane tyrosine kinase receptor that promotes cell proliferation via growth cascades. Mutations and amplifications in EGFR account for a significant fraction of non-small cell lung carcinomas and breast adenocarcinoma, with L858R being the most common oncogenic hotspot. Other glycosylation sites on EGFR have been implicated in ligand binding, dimerization, and phosphorylation of downstream targets. Molecular dynamic simulations suggested that N361 may be important for dimerization or ligand binding. However, the functional relevance of how glycosylation of EGFR at N361 impacts EGFR protein and cellular behaviors remains unclear. To determine the functional relevance of glycosylation at N361, we created glycosylation-defective EGFR N361A mutant, with or without an additional oncogenic EGFR L858R mutant. We expressed these constructs in MCF10A and 293T cells, which do not have pre-existing activation of this pathway. Immunofluorescence and flow cytometry showed that the mutants were each well expressed at the cell membrane. Proximity ligation assays measuring dimerization of EGFR in cells showed that EGFR N361A greatly increased dimerization relative to wildtype controls. Loss of glycosylation of EGFR N361 impacted cell viability when grown in dose courses of its high affinity ligand EGF or lower affinity ligand amphiregulin. Furthermore, EGFR N361A desensitized cells expressing the oncogenic EGFR L858R to inhibitors targeting the extracellular domain, possibly because the mutation alters the antibody binding interface. N361A sensitized EGFR L858R to inhibitors targeting the cytoplasmic domain of EGFR. These findings help us understand the intricate relationship between EGFR and N-glycosylation, reinforcing the critical functional relevance of post-translational modifications on oncogenes. Citation Format: Dennis Lam, Ariel N. Liberchuk, Brandon Arroyo, Andrew L. Wolfe. Mechanistic effects of N361 glycosylation in epidermal growth factor receptor protein [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4365.

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

Abstract 5132: Hypo-glycosylation of Vascular Endothelial Growth Factor Receptor-1 May Contribute to Intracrine Signaling in Human Colorectal Cancer Cells

Abstract 4365: Mechanistic effects of N361 glycosylation in epidermal growth factor receptor protein

N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation

Glycosylation at Asn254 Is Required for the Activation of the PDGF-C Protein

N-glycosylation of α1D-adrenergic receptor N-terminal domain is required for correct trafficking, function, and biogenesis

Glycosylation alters dimerization properties of a cell-surface signaling protein, CEACAM1

N-acetylglucosaminyltransferase V modifies the signaling pathway of epidermal growth factor receptor

Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor

N-Glycosylation of Integrin Α5 Acts As a Switch for EGFR-mediated Complex Formation of Integrin Α5β1 to Α6β4

N-glycosylation of the β2 adrenergic receptor regulates receptor function by modulating dimerization

Carboxy-Terminal Truncations Of Epidermal Growth-Factor (Egf) Receptor Affect Diverse Egf-Induced Cellular-Responses

Function Characterization of a Glyco-Engineered Anti-Egfr Monoclonal Antibody Cetuximab in Vitro

N-Glycosylation at Asn Residues 554 and 566 of E-Cadherin Affects Cell Cycle Progression Through Extracellular Signal-Regulated Protein Kinase Signaling Pathway

Glycosylation Alters Dimerization Properties of a Cell-surface Signaling Protein, Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1)

Mutation Specific Functions of Egfr Result in A Mutation-Specific Down Stream Pathway Activation

The effect of glycosylation trimming enzyme inhibitors on monoclonal antibody recognition of alpha-sialoglycoprotein epitopes

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors